EquitySector - HealthcareVery High Risk
Direct
NAV (06-Jun-25)
Returns (Since Inception)
Fund Size
₹3,671 Cr
Expense Ratio
0.90%
ISIN
INF200K01UP2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
01 Jan 2013
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+23.22%
+18.85% (Cat Avg.)
3 Years
+28.93%
+23.72% (Cat Avg.)
5 Years
+25.06%
+21.49% (Cat Avg.)
10 Years
+13.45%
+13.98% (Cat Avg.)
Since Inception
+18.23%
— (Cat Avg.)
Equity | ₹3,575.01 Cr | 97.40% |
Others | ₹95.6 Cr | 2.60% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹513.04 Cr | 13.98% |
Divi's Laboratories Ltd | Equity | ₹243.48 Cr | 6.63% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹230.62 Cr | 6.28% |
Cipla Ltd | Equity | ₹186.01 Cr | 5.07% |
Lonza Group Ltd ADR | Equity | ₹182.34 Cr | 4.97% |
Lupin Ltd | Equity | ₹176.03 Cr | 4.80% |
Poly Medicure Ltd | Equity | ₹139 Cr | 3.79% |
Mankind Pharma Ltd | Equity | ₹138.06 Cr | 3.76% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹133.63 Cr | 3.64% |
Jupiter Life Line Hospitals Ltd | Equity | ₹117.41 Cr | 3.20% |
Fortis Healthcare Ltd | Equity | ₹115.17 Cr | 3.14% |
Ami Organics Ltd | Equity | ₹113.06 Cr | 3.08% |
Aether Industries Ltd | Equity | ₹112.75 Cr | 3.07% |
Abbott India Ltd | Equity | ₹107.95 Cr | 2.94% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹106.04 Cr | 2.89% |
Alkem Laboratories Ltd | Equity | ₹102.32 Cr | 2.79% |
Torrent Pharmaceuticals Ltd | Equity | ₹99.66 Cr | 2.72% |
Aurobindo Pharma Ltd | Equity | ₹98.33 Cr | 2.68% |
Laurus Labs Ltd | Equity | ₹90.58 Cr | 2.47% |
Rainbow Childrens Medicare Ltd | Equity | ₹88.43 Cr | 2.41% |
Gland Pharma Ltd | Equity | ₹75.6 Cr | 2.06% |
Biocon Ltd | Equity | ₹64.36 Cr | 1.75% |
Treps | Cash - Repurchase Agreement | ₹63.58 Cr | 1.73% |
Suven Pharmaceuticals Ltd | Equity | ₹61.4 Cr | 1.67% |
Concord Biotech Ltd | Equity | ₹60.74 Cr | 1.65% |
Vijaya Diagnostic Centre Ltd | Equity | ₹60.03 Cr | 1.64% |
Pfizer Ltd | Equity | ₹42.93 Cr | 1.17% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹42.23 Cr | 1.15% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹37.05 Cr | 1.01% |
Gufic Biosciences Ltd | Equity | ₹36.77 Cr | 1.00% |
Net Receivable / Payable | Cash - Collateral | ₹29.04 Cr | 0.79% |
182 DTB 05062025 | Bond - Gov't/Treasury | ₹2.98 Cr | 0.08% |
Large Cap Stocks
28.39%
Mid Cap Stocks
28.14%
Small Cap Stocks
35.90%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹3,349.2 Cr | 91.24% |
Basic Materials | ₹225.81 Cr | 6.15% |
Standard Deviation
This fund
13.98%
Cat. avg.
16.03%
Lower the better
Sharpe Ratio
This fund
1.39
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since June 2011
ISIN INF200K01UP2 | Expense Ratio 0.90% | Exit Load No Charges | Fund Size ₹3,671 Cr | Age 12 years 5 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹11,01,967 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (06-Jun-25)
Returns (Since Inception)
Fund Size
₹3,671 Cr
Expense Ratio
0.90%
ISIN
INF200K01UP2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
01 Jan 2013
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+23.22%
+18.85% (Cat Avg.)
3 Years
+28.93%
+23.72% (Cat Avg.)
5 Years
+25.06%
+21.49% (Cat Avg.)
10 Years
+13.45%
+13.98% (Cat Avg.)
Since Inception
+18.23%
— (Cat Avg.)
Equity | ₹3,575.01 Cr | 97.40% |
Others | ₹95.6 Cr | 2.60% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹513.04 Cr | 13.98% |
Divi's Laboratories Ltd | Equity | ₹243.48 Cr | 6.63% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹230.62 Cr | 6.28% |
Cipla Ltd | Equity | ₹186.01 Cr | 5.07% |
Lonza Group Ltd ADR | Equity | ₹182.34 Cr | 4.97% |
Lupin Ltd | Equity | ₹176.03 Cr | 4.80% |
Poly Medicure Ltd | Equity | ₹139 Cr | 3.79% |
Mankind Pharma Ltd | Equity | ₹138.06 Cr | 3.76% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹133.63 Cr | 3.64% |
Jupiter Life Line Hospitals Ltd | Equity | ₹117.41 Cr | 3.20% |
Fortis Healthcare Ltd | Equity | ₹115.17 Cr | 3.14% |
Ami Organics Ltd | Equity | ₹113.06 Cr | 3.08% |
Aether Industries Ltd | Equity | ₹112.75 Cr | 3.07% |
Abbott India Ltd | Equity | ₹107.95 Cr | 2.94% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹106.04 Cr | 2.89% |
Alkem Laboratories Ltd | Equity | ₹102.32 Cr | 2.79% |
Torrent Pharmaceuticals Ltd | Equity | ₹99.66 Cr | 2.72% |
Aurobindo Pharma Ltd | Equity | ₹98.33 Cr | 2.68% |
Laurus Labs Ltd | Equity | ₹90.58 Cr | 2.47% |
Rainbow Childrens Medicare Ltd | Equity | ₹88.43 Cr | 2.41% |
Gland Pharma Ltd | Equity | ₹75.6 Cr | 2.06% |
Biocon Ltd | Equity | ₹64.36 Cr | 1.75% |
Treps | Cash - Repurchase Agreement | ₹63.58 Cr | 1.73% |
Suven Pharmaceuticals Ltd | Equity | ₹61.4 Cr | 1.67% |
Concord Biotech Ltd | Equity | ₹60.74 Cr | 1.65% |
Vijaya Diagnostic Centre Ltd | Equity | ₹60.03 Cr | 1.64% |
Pfizer Ltd | Equity | ₹42.93 Cr | 1.17% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹42.23 Cr | 1.15% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹37.05 Cr | 1.01% |
Gufic Biosciences Ltd | Equity | ₹36.77 Cr | 1.00% |
Net Receivable / Payable | Cash - Collateral | ₹29.04 Cr | 0.79% |
182 DTB 05062025 | Bond - Gov't/Treasury | ₹2.98 Cr | 0.08% |
Large Cap Stocks
28.39%
Mid Cap Stocks
28.14%
Small Cap Stocks
35.90%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹3,349.2 Cr | 91.24% |
Basic Materials | ₹225.81 Cr | 6.15% |
Standard Deviation
This fund
13.98%
Cat. avg.
16.03%
Lower the better
Sharpe Ratio
This fund
1.39
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since June 2011
ISIN INF200K01UP2 | Expense Ratio 0.90% | Exit Load No Charges | Fund Size ₹3,671 Cr | Age 12 years 5 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹11,01,967 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments